Catalyst Pharmaceuticals (CPRX) Jefferies 2024 Global Healthcare Conference summary

Strategic overview and portfolio highlights

• Focus on rare diseases with a diversified portfolio, including neuromuscular and epilepsy franchises, and recent expansion through acquisitions.

• Firdapse leads the neuromuscular franchise, with strong IP protection through 2037 and orphan drug exclusivity until 2025.

• Agamree, recently launched for Duchenne muscular dystrophy, addresses unmet needs with improved safety and efficacy over traditional steroids.

• Fycompa, acquired in 2023, expands the epilepsy franchise and offers a unique mechanism of action for seizure control.

• Ongoing efforts to expand product indications, geographic reach, and lifecycle management for all key assets.

Market opportunities and growth drivers

• Firdapse targets a U.S. prevalence of 3,600–5,400 patients, with additional opportunities in Canada and Japan; Japanese launch expected in 2025.

• Agamree serves 11,000–13,000 DMD patients in the U.S., with high diagnosis and steroid usage rates.

• Fycompa addresses a large epilepsy market (3.4 million U.S. patients), with 30–40% of patients lacking full seizure control.

• Synergies in sales and marketing across franchises enhance efficiency and market penetration.

• Strategic partnerships and global expansion are ongoing to unlock new territories and indications.

Financial performance and outlook

• Q1 year-over-year revenue growth: Firdapse up to $67M, Fycompa to $30M, Agamree launched with $1M in two weeks.

• Total quarterly revenue increased from $85M to $99M, with overall net product revenue up 15%.

• Non-GAAP net income considered a better performance indicator due to acquisition-related accounting.

• Cash position at $310M, with $20–$25M added to the bottom line per quarter, supporting future acquisitions.

• Continued organic growth in core products, with Agamree expected to drive future revenue increases.